Compare GSK plc (GSK) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Zoom Video Communications, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: GSK plc is far larger — about 3.3× Zoom Video Communications, Inc.'s market cap, and GSK plc pays a 3.9% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Zoom Video Communications, Inc. for 92 Days on average.
| GSK | ZM | |
|---|---|---|
Market Cap | $91.88B | $27.62B |
Volume | 7,730,529 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $61.18 | $111.88 |
52-Week Low | $43.24 | $72.72 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $111.88B | $20.43B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Zoom Communications (ZM) trades at $97.74, up 3.13% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a net income margin of 65.19% and ROE of 32.14%, though recent earnings were mixed with one miss and two beats. Revenue growth is steady, projected to reach $5.0B in 2026, and the company is actively investing in AI-driven revenue tools, as highlighted by recent product launches.
The outlook for ZM is positive, with a consensus price target of $118.08 offering ~21% upside, supported by analyst buy ratings. Key risks include reliance on international sales and competitive pressures in the communication software space. Cash flow trends show variability, with net cash flow negative in 2025 and 2026, requiring monitoring of capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
